IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 512,788 shares of the company’s stock after purchasing an additional 59,519 shares during the period. Dimensional Fund Advisors LP owned about 0.62% of IDEXX Laboratories worth $249,855,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in IDXX. Riverview Trust Co acquired a new stake in IDEXX Laboratories during the 1st quarter worth $26,000. Crewe Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the first quarter worth about $26,000. Ridgewood Investments LLC purchased a new position in shares of IDEXX Laboratories during the second quarter worth about $27,000. Institutional & Family Asset Management LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at about $28,000. Finally, DSM Capital Partners LLC purchased a new stake in IDEXX Laboratories during the 4th quarter valued at approximately $33,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on IDXX. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Finally, Piper Sandler dropped their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Price Performance

IDXX stock opened at $511.30 on Thursday. The stock’s 50 day moving average price is $482.98 and its 200 day moving average price is $499.90. The firm has a market cap of $42.23 billion, a P/E ratio of 49.50, a PEG ratio of 4.17 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the firm posted $2.67 EPS. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.